JPWO2020021437A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020021437A5 JPWO2020021437A5 JP2021503095A JP2021503095A JPWO2020021437A5 JP WO2020021437 A5 JPWO2020021437 A5 JP WO2020021437A5 JP 2021503095 A JP2021503095 A JP 2021503095A JP 2021503095 A JP2021503095 A JP 2021503095A JP WO2020021437 A5 JPWO2020021437 A5 JP WO2020021437A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- agonist
- interferon type
- tumor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 claims 45
- 206010028980 Neoplasm Diseases 0.000 claims 37
- 102000008070 Interferon-gamma Human genes 0.000 claims 23
- 108010074328 Interferon-gamma Proteins 0.000 claims 23
- 229940028894 interferon type ii Drugs 0.000 claims 23
- 102000002227 Interferon Type I Human genes 0.000 claims 22
- 108010014726 Interferon Type I Proteins 0.000 claims 22
- 239000002246 antineoplastic agent Substances 0.000 claims 22
- 230000001580 bacterial effect Effects 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 13
- 201000000053 blastoma Diseases 0.000 claims 7
- 201000008184 embryoma Diseases 0.000 claims 7
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 6
- 102000006240 membrane receptors Human genes 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 230000002496 gastric effect Effects 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 230000000242 pagocytic effect Effects 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- SLURUCSFDHKXFR-WWMWMSKMSA-N (7s,9s)-7-[[(1s,3r,4as,9s,9ar,10as)-9-methoxy-1-methyl-3,4,4a,6,7,9,9a,10a-octahydro-1h-pyrano[1,2][1,3]oxazolo[3,4-b][1,4]oxazin-3-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=CC=CC(OC)=C2C(=O)C(C(O)=C23)=C1C(O)=C3C[C@@](O)(C(=O)CO)C[C@@H]2O[C@H]1C[C@@H]2N3CCO[C@H](OC)[C@H]3O[C@@H]2[C@H](C)O1 SLURUCSFDHKXFR-WWMWMSKMSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 241000234671 Ananas Species 0.000 claims 2
- 235000007119 Ananas comosus Nutrition 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 2
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 2
- JMENXJYBCQFIRK-KRJDXUSZSA-N N-hexacosanoylisoglobotriaosyl ceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 JMENXJYBCQFIRK-KRJDXUSZSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 201000008183 Pulmonary blastoma Diseases 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 229940106189 ceramide Drugs 0.000 claims 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 2
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 210000000115 thoracic cavity Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- IRPOZWRRAFKYMQ-LMIAXWKISA-N 1-O-(alpha-D-galactopyranuronosyl)-N-tetradecanoyldihydrosphingosine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](NC(=O)CCCCCCCCCCCCC)CO[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O IRPOZWRRAFKYMQ-LMIAXWKISA-N 0.000 claims 1
- FJAAFGBZVPKOCR-HBHGLPGMSA-N 1-palmitoyl-2-cis-vaccenoyl-3-alpha-D-glucosyl-sn-glycerol Chemical compound CCCCCC\C=C/CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FJAAFGBZVPKOCR-HBHGLPGMSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 101800002638 Alpha-amanitin Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- YPMUZVRAVKLKGC-UHFFFAOYSA-N BBGL-II Natural products OC1C(O)C(O)C(COC(=O)CCCCCCCCCCCCCCC)OC1OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 YPMUZVRAVKLKGC-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 229930182476 C-glycoside Natural products 0.000 claims 1
- 150000000700 C-glycosides Chemical class 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- 239000012623 DNA damaging agent Substances 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000010505 Nose Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012648 POLY-ICLC Substances 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010061336 Pelvic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 208000033014 Plasma cell tumor Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000009572 RNA Polymerase II Human genes 0.000 claims 1
- 108010009460 RNA Polymerase II Proteins 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 claims 1
- 229940044665 STING agonist Drugs 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 229940124614 TLR 8 agonist Drugs 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 108091027569 Z-DNA Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 239000004007 alpha amanitin Substances 0.000 claims 1
- MYYARUCLXARAEE-ZATZPJRKSA-N alpha-C-GalCer Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCCCCC MYYARUCLXARAEE-ZATZPJRKSA-N 0.000 claims 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 claims 1
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 claims 1
- YIGARKIIFOHVPF-CNUVFPMCSA-N beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YIGARKIIFOHVPF-CNUVFPMCSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002308 embryonic cell Anatomy 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 150000002224 folic acids Chemical class 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000002529 islet cell tumor Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 claims 1
- 208000037830 nasal cancer Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 claims 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 208000029211 papillomatosis Diseases 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 208000023974 pharynx neoplasm Diseases 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 208000020943 pineal parenchymal cell neoplasm Diseases 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 108700002563 poly ICLC Proteins 0.000 claims 1
- 229940115270 poly iclc Drugs 0.000 claims 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003212 purines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 210000005132 reproductive cell Anatomy 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 201000008261 skin carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 210000003741 urothelium Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 229960005502 α-amanitin Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023222336A JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702172P | 2018-07-23 | 2018-07-23 | |
| US62/702,172 | 2018-07-23 | ||
| US201962788265P | 2019-01-04 | 2019-01-04 | |
| US62/788,265 | 2019-01-04 | ||
| PCT/IB2019/056259 WO2020021437A1 (en) | 2018-07-23 | 2019-07-22 | Compositions comprising bacterially derived minicells and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222336A Division JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532106A JP2021532106A (ja) | 2021-11-25 |
| JPWO2020021437A5 true JPWO2020021437A5 (https=) | 2022-06-28 |
| JP2021532106A5 JP2021532106A5 (https=) | 2022-06-28 |
Family
ID=69181384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503095A Pending JP2021532106A (ja) | 2018-07-23 | 2019-07-22 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
| JP2023222336A Pending JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222336A Pending JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11504402B2 (https=) |
| EP (1) | EP3826654A4 (https=) |
| JP (2) | JP2021532106A (https=) |
| CN (1) | CN112689511A (https=) |
| AU (2) | AU2019311380B2 (https=) |
| CA (1) | CA3107095A1 (https=) |
| SG (1) | SG11202100507PA (https=) |
| WO (1) | WO2020021437A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2858315C (en) | 2011-12-13 | 2020-05-12 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| CN106999444B (zh) * | 2014-10-03 | 2023-12-12 | 安吉尼科分子传输公司 | 完整的细菌衍生的囊泡对小分子化合物的增强装载 |
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| BR112020005803A2 (pt) | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| CN113507936A (zh) * | 2019-01-04 | 2021-10-15 | 安吉尼科分子传输公司 | 用于治疗赘生性疾病的包封的糖脂抗原 |
| WO2021191796A1 (en) * | 2020-03-24 | 2021-09-30 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing viral infections, including coronavirus infections, and methods of using the same |
| US12357687B2 (en) | 2020-03-24 | 2025-07-15 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same |
| WO2022093729A1 (en) * | 2020-10-27 | 2022-05-05 | Rutgers, The State University Of New Jersey | Replication-defective vaccines and uses thereof |
| CN114569627A (zh) * | 2020-12-02 | 2022-06-03 | 杭州星鳌生物科技有限公司 | 新型sting激动剂复合物的制备、组成及其在抗肿瘤药物中的应用 |
| US12551550B2 (en) | 2021-07-22 | 2026-02-17 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same |
| WO2023002433A1 (en) * | 2021-07-22 | 2023-01-26 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same |
| CN121285390A (zh) * | 2023-04-17 | 2026-01-06 | 安吉尼科分子传输公司 | 用于递送α-半乳糖神经酰胺化合物的组合物和方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747002B2 (en) | 1999-05-11 | 2004-06-08 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| ATE541940T1 (de) | 2001-10-15 | 2012-02-15 | Engeneic Molecular Delivery Pty Ltd | Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| CN101954095B (zh) | 2003-12-09 | 2013-03-13 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP1718338B1 (en) | 2004-02-02 | 2015-05-06 | EnGeneIC Molecular Delivery Pty Ltd. | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP2386640B1 (en) * | 2004-08-26 | 2015-01-28 | EnGeneIC Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| NZ573689A (en) | 2006-05-22 | 2011-03-31 | Univ New York | C-glycolipids with enhanced TH-1 profile |
| US9878043B2 (en) | 2006-06-23 | 2018-01-30 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| DK2865755T3 (en) | 2007-03-30 | 2017-05-15 | Engeneic Molecular Delivery Pty Ltd | BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA |
| JP2010523724A (ja) | 2007-04-13 | 2010-07-15 | アカデミア シニカ | α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用 |
| DK2385980T3 (en) | 2009-01-08 | 2018-07-30 | Albert Einstein College Medicine Inc | BACTERIA VACCINES WITH CELL-WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND APPLICATIONS THEREOF |
| EP2496714B1 (en) * | 2009-11-04 | 2016-08-31 | DiamiR, LLC | Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment |
| ES2828092T3 (es) | 2012-10-02 | 2021-05-25 | Vaxiion Therapeutics Llc | Minicélulas inmunomoduladoras y métodos de uso |
| US9006200B2 (en) * | 2013-03-13 | 2015-04-14 | Asbestos Diseases Research Foundation | MicroRNA-based approach to treating malignant pleural mesothelioma |
| SG11201602429QA (en) * | 2013-10-04 | 2016-04-28 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
| KR20160106170A (ko) | 2014-01-22 | 2016-09-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체 및 항체-부하된 수지상 세포 매개된 요법을 위한 방법 및 조성물 |
| US10913940B2 (en) | 2016-04-11 | 2021-02-09 | University Of Virginia | Compositions and methods for pesticide degradation |
| AU2017339841B2 (en) * | 2016-10-06 | 2024-11-14 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
-
2019
- 2019-07-22 JP JP2021503095A patent/JP2021532106A/ja active Pending
- 2019-07-22 SG SG11202100507PA patent/SG11202100507PA/en unknown
- 2019-07-22 CA CA3107095A patent/CA3107095A1/en active Pending
- 2019-07-22 US US16/518,833 patent/US11504402B2/en active Active
- 2019-07-22 WO PCT/IB2019/056259 patent/WO2020021437A1/en not_active Ceased
- 2019-07-22 AU AU2019311380A patent/AU2019311380B2/en active Active
- 2019-07-22 CN CN201980060185.6A patent/CN112689511A/zh active Pending
- 2019-07-22 EP EP19839892.7A patent/EP3826654A4/en active Pending
-
2022
- 2022-11-18 US US17/990,402 patent/US12414968B2/en active Active
-
2023
- 2023-12-28 JP JP2023222336A patent/JP2024038199A/ja active Pending
-
2026
- 2026-03-17 AU AU2026202046A patent/AU2026202046A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532106A5 (https=) | ||
| JP7459168B2 (ja) | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 | |
| US11702476B2 (en) | Anti-EGFR combinations for treating tumors | |
| JPWO2020021437A5 (https=) | ||
| US20220204641A1 (en) | Anti-cd20 combinations for treating tumors | |
| US10945955B2 (en) | Artificial exosome composition and related methods | |
| US20210347911A1 (en) | Anti-her2 combinations for treating tumors | |
| US9701962B2 (en) | Hydrophobically modified antisense oligonucleotides comprising a ketal group | |
| JP6741673B2 (ja) | 抗ｔｎｆ化合物 | |
| CN108779463B (zh) | 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘 | |
| US20180042848A1 (en) | Immuno-regulatory lipid containing spherical nucleic acids | |
| JP2016532639A (ja) | 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療 | |
| WO2016149323A1 (en) | Immunomodulatory spherical nucleic acids | |
| KR20180118716A (ko) | Ｄｂａｉｔ 분자의 전신 투여에 의한 암 치료법 | |
| TW201141489A (en) | Organic compositions to treat Beta-ENaC-related diseases | |
| US20210095284A1 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| JP2020537688A (ja) | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド | |
| WO2022031237A1 (en) | Modulation of signal transducer and activator of transcription 3 (stat3) expression | |
| US20250243491A1 (en) | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof | |
| US20240124875A1 (en) | Rnai conjugates and uses thereof | |
| JP2024539435A (ja) | がんの免疫療法的治療のためのｃＧＡＳ－ＳＴＩＮＧ及びＳＴＡＴ３経路変調のための球状核酸 | |
| TW202334415A (zh) | 治療與膽汁酸轉運體相關之疾病的組合物及方法 | |
| JP6794258B2 (ja) | オリゴヌクレオチドについてのホスホロジアミデート骨格結合 | |
| CN121816417A (zh) | 双链寡核苷酸药剂和其用途 | |
| TW202400786A (zh) | 具有RNAi活性的化學修飾寡核苷酸 |